Targovax — Growing list of collaborations and more data in H2

Targovax (NO: TRVX)

Last close As at 21/11/2024

9.07

0.00 (0.00%)

Market capitalisation

785m

More on this equity

Research: Healthcare

Targovax — Growing list of collaborations and more data in H2

An update from Targovax’s Phase I/II study in unresectable mesothelioma with OCOS-102 was the highlight of Q220 (described in our last note). Median over survival (OS) data are still not mature and the next update in expected by year-end. Another catalyst expected this year is the results of Part 2 from the Phase I melanoma trial in H220. The trial aims to show ONCOS-102 can activate the immune response in anti-PD1 refractory patients. Following the cost-reduction programme implemented in 2019, Targovax is now sharply focused on its oncolytic virus platform. However, after signing a string of new collaborations, the company is now involved in multiple projects, which significantly increase profit opportunities. Our valuation is unchanged at NOK1.65bn or NOK21.6/share.

Analyst avatar placeholder

Written by

Healthcare

Targovax

Growing list of collaborations and more data in H2

Company update

Pharma & biotech

17 September 2020

Price

NOK7.2

Market cap

NOK551m

Net cash (NOKm) at end Q220

101.5

Shares in issue

76.1m

Free float

90%

Code

TRVX

Primary exchange

Oslo Stock Exchange

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

13.1

-2.8

40.6

Rel (local)

14.8

-4.4

58.3

52-week high/low

NOK10.2

NOK3.7

Business description

Targovax is an immunoncology company headquartered in Oslo, Norway, developing an oncolytic virus platform, ONCOS. ONCOS-102 is prioritised in several indications including mesothelioma and melanoma. Targovax is also working on next-generation oncolytic viruses in its preclinical R&D pipeline.

Next events

Cohort 2 data from Phase I melanoma

2020

Patient survival update from Phase I/II study

H220

Q320 results

5 November 2020

Analyst

Jonas Peciulis

+44 (0)20 3077 5728

Targovax is a research client of Edison Investment Research Limited

An update from Targovax’s Phase I/II study in unresectable mesothelioma with OCOS-102 was the highlight of Q220 (described in our last note). Median over survival (OS) data are still not mature and the next update in expected by year-end. Another catalyst expected this year is the results of Part 2 from the Phase I melanoma trial in H220. The trial aims to show ONCOS-102 can activate the immune response in anti-PD1 refractory patients. Following the cost-reduction programme implemented in 2019, Targovax is now sharply focused on its oncolytic virus platform. However, after signing a string of new collaborations, the company is now involved in multiple projects, which significantly increase profit opportunities. Our valuation is unchanged at NOK1.65bn or NOK21.6/share.

Year end

Revenue (NOKm)

PBT*
(NOKm)

EPS*
(NOK)

DPS
(NOK)

P/E
(x)

Yield
(%)

12/18

0.0

(147.3)

(2.8)

0.0

N/A

N/A

12/19

2.3

(147.9)

(2.4)

0.0

N/A

N/A

12/20e

0.0

(124.5)

(1.8)

0.0

N/A

N/A

12/21e

0.0

(126.3)

(1.7)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

More newsflow from both trials this year

On 22 June 2020, Targovax reported additional data from its Phase I/II study in unresectable mesothelioma (follow-up to the first data published in January 2020). There were no new safety issues and the efficacy signals seen in the first set of data were confirmed. The immune and gene sequencing data provided strong support for ONCOS-102’s ability to activate the immune system and remodel the tumour microenvironment. Median OS data are still not mature and the next update is expected before the end of 2020. Targovax should also report Part 2 results from the Phase I melanoma trial in H220. In this study patients are administered a combination of ONCOS-102 and Keytruda with the goal to show ONCOS-102 can activate the immune response in anti-PD1 refractory patients.

Growing list of collaborations

Targovax’s focus and investment areas are the ongoing lead clinical trials with ONCOS-102 and preclinical work on the new generation of oncolytic viruses. Over the past year, however, the company has established a number of partnerships focused on early-stage exploratory projects. In these types of collaborations, Targovax typically provides access to its technology and support, but financial involvement is limited. Because the company still contributes its intellectual property, any potentially successful combination therapies would mean a licensing deal for Targovax. So, it is a good way to enhance future profit opportunities in a cost-efficient manner.

Valuation: NOK1.65bn or NOK21.6/share

Our valuation is unchanged at NOK1.65bn or NOK21.6/share, as lower cash position offset rolling the model forward. Cash and cash equivalents were NOK101m at the end of Q220, which secures funding into 2021.

Targovax’s key collaborations

Although all current collaborations are fairly early stage (except IOVaxis, which could start a clinical stage trial soon), as we described above, it is a cost-efficient way to increase future opportunities. One additional benefit is that many of these collaborations include Targovax’s TG platform. Although the company has deprioritised this technology in favour of ONCOS, the mutant RAS target is one of the most promising, but also difficult, targets in oncology and attracts a lot of attention due to its involvement in many major cancer indications. The high interest in this target is demonstrated by the fact that four of Targovax’s collaborations are centred on mutant RAS (Exhibit 1).

The current list of collaborations includes:

Leidos. In June 2020, Targovax signed a collaboration agreement with the Explorations in Global Health (ExGloH) Division of Leidos Holdings (NYSE/Nasdaq, market cap $13bn). ExGLoH has developed a unique portfolio of peptides that can bind checkpoint receptors and act as antagonists, called Microtide technology. Because the structure of these peptides is much smaller than traditional checkpoint inhibitors (CPIs, monoclonal antibodies), they can be encoded in viral vectors, in this case Targovax’s ONCOS. This could potentially result in a ‘two-in-one’ approach instead of administering ONCOS and CPIs separately. According to current agreement terms, Leidos and Targovax will conduct in vitro and in vivo feasibility studies. In our view, although this is still a relatively early exploration project, the approach is cutting-edge science in immunoncology. In addition, Leidos is a large company, so a strong partner if the project should advance. Targovax is already focused on developing its ONCOS-102 in combinations with CPIs, as there is a strong rationale for such combinations. Immune primers, such as ONCOS-102, help to generate the anti-tumour immune response, while CPIs block the tumour’s defence mechanism against the patient’s immune system.

IOVaxis Therapeutics. In January 2020, Targovax signed an exclusive option agreement with IOVaxis Therapeutics, a spin-off from China-based, privately owned ImmuOn Therapeutics. IOVaxis acquired an option to in-license the rights to Targovax’s mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore. The option is exercisable as soon as the regulator approves the first clinical trial, but no later than one year after the agreement (so that Targovax would avoid delays). The option deal is structured to take into account the uncertainty over how the Chinese regulatory authority treats therapies such as cancer vaccines. Targovax received $250k for the option and another $3m is due as an upfront payment on exercise of the option. Total potential development and commercial milestones are up to $100m, plus mid double-digit royalties. Targovax has deprioritised its TG vaccines against mutant RAS to focus on its ONCOS platform even though the Phase II data were promising (described in detail in our previous reports). Although the agreement involves only China rights, we believe that if this project is successful and delivers another batch of promising data, the interest in the TG rights to other regions would increase significantly.

Oblique. In June 2020, Targovax singed a collaboration with a privately held Swedish biotech Oblique Therapeutics. Oblique has developed a proprietary antibody platform Abiprot, which can identify high-affinity antibody binding sites in any given protein. One of the targets Oblique is interested in is mutant RAS. Oblique’s challenge is to introduce its antibodies into the cells with mutated RAS. The collaboration aims to evaluate in vitro and in vivo the potential of using ONCOS oncolytic adenoviruses as a vector to encode and deliver Abiprot antibodies intracellularly to boost the efficacy.

Valo. In April 2020, Targovax entered in a collaboration agreement with Valo Therapeutics to work on a project, where Valo's peptide-coating technology PeptiCDAd will be used to coat ONCOS oncolytic adenoviruses with Targovax’s TG mutant RAS peptides. Valo, with headquarters in Helsinki, Finland, and Oxford, UK, has developed a platform, PeptiCRAd, that allows the coating of oncolytic viruses with antigens. This is a simpler process than genetically engineering antigens into an oncolytic virus genome and is very adaptive – the same carrier virus can be coated with different antigens and target different mutations. The rationale is that coated oncolytic viruses deliver the antigens directly into the tumour, which results in increased immunogenicity and CD8+ T-cell response against tumour tissue. Targovax has IP on both components, the oncolytic virus (ONCOS) and the mutant RAS peptides (TG), so there will be no need to in-license any other technology. Initially, the collaboration is focused on technical feasibility, in vitro activity and in vivo immune activation studies. If successful, this project could result in a new generation of Targovax’s ONCOS oncolytic viruses.

Zelluna. Targovax has another agreement in place with a Norwegian biotech Zelluna Immunotherapy, which is working on T cell receptor guided natural killer cell (TCR-NK) technology. Zelluna engineers allogeneic NK cells to expresses a TCR of choice, which would result in a novel cell immunotherapy theoretically able to recognise any antigen on a surface of a cancer cell. One of the projects Zelluna is working on is mutant RAS TCRs therapy, for which Targovax agreed to out-license its IP and know how. Zelluna has been granted a global, non-exclusive license to relevant patents, while the potential deal value for Targovax is up to NOK100m and royalty payments.

Exhibit 1: Targovax’s partnerships

Source: Targovax

Upcoming newsflow

We provided a detailed discussion about Targovax’s R&D progress in our previous reports. Both key clinical trials will continue generating data in the near term. Targovax’s preclinical development of the new generation of oncolytic viruses is also advancing.

Exhibit 2: Targovax’s R&D pipeline and upcoming newsflow

Source: Targovax

Mesothelioma: Patient survival update by end-2020

On 22 June 2020, Targovax reported additional data from its Phase I/II study in unresectable mesothelioma (follow-up to the first data published in January 2020). There were no new safety issues and the efficacy signals seen in the first set of results were confirmed. Importantly, the immune and gene sequencing data provided strong support for ONCOS-102’s ability to activate the immune system and remodel the tumour microenvironment. Detailed analysis is presented in our last report. Median OS data are still not mature and a patient survival update is expected before the end of 2020.

Targovax reiterated its plans to explore ONCOS-102 in triple combination with a CPI and standard chemotherapy in first line. These plans are still at a preliminary stage, but there is potential for the study to become a registrational programme due to a high unmet need in mesothelioma. One significant positive step towards the triple combination trial was the announcement that Merck & Co will supply Keytruda (pembrolizumab, anti-PD-1). Because of high costs, combinations with CPIs can rapidly inflate the cost of clinical trials, so a supply agreement has a direct positive financial effect for the trial sponsor.

Melanoma: Results from Part 2 of Phase I study in H220

The ongoing Phase I trial enrolled patients with advanced, unresectable melanoma who progressed on treatment with anti-PD1 checkpoint inhibitors. ONCOS-102 is administered in combination with the CPI pembrolizumab (Keytruda, Merck & Co). The trial aims to show ONCOS-102 can activate the immune response in anti-PD1 refractory patients, trigger relevant T-cell production and enhance their infiltration into the tumour. The goal is to allow the patients to benefit from treatment with CPI again.

Part 2 of the Phase I melanoma trial is fully enrolled and the readout from it will be the key catalyst expected in H220. Patients are being administered with significantly extended dosing of ONCOS-102 compared to patients in Part 1. Data from the Part 1 demonstrated 33% overall response rate, which compared well with other similar studies and evidence of systemic anti-tumour response.

ONCOS-200: New oncolytic viruses

In second-generation ONCOS viruses, Targovax was able to add double transgenes (the first-generation ONCOS-102 has granulocyte macrophage colony stimulating factor). These new viruses have different properties and are optimised to inhibit tumour growth and vascularisation, counteract the immunosuppressive tumour microenvironment or have enhanced cell-killing properties. Targovax presented preclinical in vitro and in vivo data at the American Association for Cancer Research Virtual Annual Meeting in June 2020 from its studies with the ONCOS-210 and 212 viruses demonstrating anti-cancer properties and that the double transgenes act synergistically. We expect more data in the near future, including more details about positioning in the clinic and which indications will be prioritised. In addition, the new collaboration with Leidos, as described above, could potentially lead to a new generation ONCOS virus.

Financials and valuation

Targovax’s Q220 operating expenses were NOK30.0m, which were significantly lower than NOK44.6m in Q219 following the cost-reduction programme (R&D spend down to NOK14.1m from NOK22.0m; payroll down to NOK11.0m from NOK17.5m). We had already cut our spending forecasts to an operating loss of NOK134.5m and NOK136.6m in 2020 and 2021 respectively and now further fine-tune by lowering operating loss to NOK124.5m and NOK126.3m in 2020 and 2021 respectively.

Targovax had cash and cash equivalents of NOK101m at the end of Q220, which secures funding into 2021 according to our model. The funding gap in 2021 (NOK81m) is covered in our model by increasing long-term debt (as per our principles; Exhibit 4).

Our valuation is unchanged at NOK1.65bn or NOK21.6/share, as lower cash position offset rolling the model forward. We continue to exclude other long-term debt of €7m in Finnish government grants from our valuation, as repayment is only required if the products are sold or launched.

Exhibit 3: Sum-of-the-parts Targovax valuation

Product

Launch

Peak sales
($m)

Unrisked NPV (NOKm)

Unrisked NPV/share (NOK)

Probability (%)

rNPV
(NOKm)

rNPV/share (NOK)

ONCOS-102 – advanced melanoma

2025

590

3,003.9

39.4

15%

764.4

10.0

ONCOS-102 – mesothelioma

2026

424

2,377.9

31.2

25%

781.7

10.3

Net cash, last reported

101.5

1.3

100%

101.5

1.3

Valuation

5,483.3

72.0

1,647.6

21.6

Source: Edison Investment Research. Note: WACC = 12.5% for product valuations. Excludes conditional government long-term loans.

Exhibit 4: Financial summary

NOK'000s

2018

2019

2020e

2021e

December

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

27

2,251

0

0

Cost of Sales

0

0

0

0

Gross Profit

27

2,251

0

0

Research and development

(64,006)

(80,286)

(60,103)

(59,913)

EBITDA

 

 

(145,804)

(146,247)

(124,508)

(126,250)

Operating Profit (before amort. and except.)

 

 

(146,100)

(150,273)

(124,508)

(126,250)

Intangible Amortisation

0

0

0

0

Exceptionals

0

0

0

0

Other

0

0

0

0

Operating Profit

(146,100)

(150,273)

(124,508)

(126,250)

Net Interest

(1,249)

2,423

0

0

Profit Before Tax (norm)

 

 

(147,349)

(147,850)

(124,508)

(126,250)

Profit Before Tax (reported)

 

 

(147,349)

(147,850)

(124,508)

(126,250)

Tax

334

321

0

0

Profit After Tax (norm)

(147,015)

(147,529)

(124,508)

(126,250)

Profit After Tax (reported)

(147,015)

(147,529)

(124,508)

(126,250)

Average Number of Shares Outstanding (m)

52.6

60.8

69.6

75.9

EPS - normalised (NOK)

 

 

(2.79)

(2.43)

(1.79)

(1.66)

EPS - normalised fully diluted (NOK)

 

 

(2.79)

(2.43)

(1.79)

(1.66)

EPS - reported (NOK)

 

 

(2.79)

(2.43)

(1.79)

(1.66)

Dividend per share (NOK)

0.0

0.0

0.0

0.0

Gross Margin (%)

100.0

100.0

N/A

N/A

EBITDA Margin (%)

N/A

N/A

N/A

N/A

Operating Margin (before GW and except.) (%)

N/A

N/A

N/A

N/A

BALANCE SHEET

Fixed Assets

 

 

371,129

371,050

371,050

371,050

Intangible Assets

370,240

367,083

367,083

367,083

Tangible Assets

889

726

726

726

Investments

0

3,241

3,241

3,241

Current Assets

 

 

166,509

85,858

52,014

16,429

Stocks

0

0

0

0

Debtors

0

0

0

0

Cash

151,189

70,429

36,585

1,000

Other

15,320

15,429

15,429

15,429

Current Liabilities

 

 

(59,377)

(50,690)

(39,756)

(43,469)

Creditors

(50,250)

(53,931)

(42,997)

(46,710)

Short term borrowings

(9,127)

0

0

0

Long Term Liabilities

 

 

(103,565)

(109,263)

(109,263)

(190,569)

Long term borrowings

(43,933)

(50,441)

(50,441)

(131,747)

Other long term liabilities

(59,632)

(58,822)

(58,822)

(58,822)

Net Assets

 

 

374,696

296,955

274,045

153,441

CASH FLOW

Operating Cash Flow

 

 

(112,816)

(140,094)

(129,796)

(116,891)

Net Interest

1,249

(2,423)

0

0

Tax

0

0

0

0

Capex

0

(134)

0

0

Acquisitions/disposals

0

0

0

0

Financing

(30)

66,863

95,950

0

Other

(3,041)

(2,353)

2

0

Dividends

0

0

0

0

Net Cash Flow

(114,638)

(78,141)

(33,844)

(116,891)

Opening net debt/(cash)

 

 

(212,767)

(98,129)

(19,988)

13,856

HP finance leases initiated

0

0

0

0

Other

0

0

0

0

Closing net debt/(cash)

 

 

(98,129)

(19,988)

13,856

130,747

Source: Targovax accounts, Edison Investment Research


General disclaimer and copyright

This report has been commissioned by Targovax and prepared and issued by Edison, in consideration of a fee payable by Targovax. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2020 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited (“FTSE”) © FTSE 2020. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

General disclaimer and copyright

This report has been commissioned by Targovax and prepared and issued by Edison, in consideration of a fee payable by Targovax. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2020 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited (“FTSE”) © FTSE 2020. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Targovax

View All

Latest from the Healthcare sector

View All Healthcare content

Research: Consumer

La Doria — Another strong set of results

During Q2, La Doria continued to benefit from the shift in consumption caused by the COVID-19 pandemic, with more food consumed at home and only a slow and partial return to the horeca channel, to which La Doria has little exposure. As in Q1, revenue growth was entirely volume-led, which benefited margins. We expect the trend to persist until at least the end of the year, as consumers continue to favour eating at home while the pandemic is ongoing. We see upside to our forecasts, as La Doria benefits from the prolonged shift in consumption.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free